Second primary cancers following hematologic malignancies: Epidemiology, pathobiology and clinical management.

Skip to main content An official website of the United States government Here's how you know Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. Search Log in Dashboard Publications Account settings Log out Search… Search NCBI Primary site navigation Search Logged in as: Dashboard Publications Account settings Log in Search PMC Full-Text Archive Search in PMC Journal List User Guide PERMALINK Copy As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright Notice Hum Vaccin Immunother . 2026 Apr 9;22(1):2654318. doi: 10.1080/21645515.2026.2654318 Search in PMC Search in PubMed View in NLM Catalog Add to search Second primary cancers following hematologic malignancies: Epidemiology, pathobiology and clinical management Yueyue Pan Yueyue Pan a Department of Laboratory Medicine, Wuxi Medical Center, Wuxi People’s Hospital, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, China Conceptualization, Writing – original draft Find articles by Yueyue Pan a , Hailing Yang Hailing Yang b Key Laboratory of Industrial Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, China Writing – review & editing Find articles by Hailing Yang b , Junliang Shao Junliang Shao a Department of Laboratory Medicine, Wuxi Medical Center, Wuxi People’s Hospital, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, China Writing – review & editing Find articles by Junliang Shao a , Xinchen Qiang Xinchen Qiang a Department of Laboratory Medicine, Wuxi Medical Center, Wuxi People’s Hospital, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, China Writing – review & editing Find articles by Xinchen Qiang a , Qiong Wang Qiong Wang a Department of Laboratory Medicine, Wuxi Medical Center, Wuxi People’s Hospital, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, China Conceptualization, Writing – review & editing Find articles by Qiong Wang a, ✉ Author information Article notes Copyright and License information a Department of Laboratory Medicine, Wuxi Medical Center, Wuxi People’s Hospital, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, China b Key Laboratory of Industrial Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, China ✉ CONTACT Qiong Wang [email protected] Wuxi Medical Center, Wuxi People’s Hospital, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, No. 299, Qingyang Road, Liangxi District, Wuxi, Jiangsu 214023, China. Roles Yueyue Pan : Conceptualization, Writing – original draft Hailing Yang : Writing – review & editing Junliang Shao : Writing – review & editing Xinchen Qiang : Writing – review & editing Qiong Wang : Conceptualization, Writing – review & editing Received 2025 Nov 7; Accepted 2026 Mar 29; Collection date 2026. © 2026 The Author(s). Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. PMC Copyright notice PMCID: PMC13078236  PMID: 41956548 ABSTRACT Second primary cancers (SPCs) pose an increasingly significant clinical challenge for survivors of hematologic malignancies, attributed to improved therapeutic outcomes and prolonged survival. The development of SPCs is influenced by a complex interplay of treatment-related factors, genetic susceptibility, immune dysregulation, and microenvironmental remodeling. This narrative review summarizes the epidemiological patterns of SPCs in survivors of hematologic malignancies and discusses the underlying biological mechanisms, including therapy-induced genomic instability, clonal hematopoiesis, inflammatory signaling, and alterations in the bone marrow microenvironment. Furthermore, we review current surveillance strategies and emerging biomarkers for early detection and risk stratification. Additionally, we discuss the potential contributions of integrated multi-omics approaches, tumor microenvironment profiling, and precision medicine strategies to SPC monitoring and prevention. Lastly, we outline future directions for clinicians and researchers, emphasizing the necessity for personalized surveillance programs, translational biomarker validation, and multidisciplinary management strategies to mitigate SPC risk in long-term survivors. KEYWORDS: Hematological malignancies, second primary cancers, chimeric antigen receptor T-cell therapy, genetic susceptibility, multidisciplinary team Introduction Hematologic malignancies, which encompass leukemia, lymphoma, and multiple myeloma (MM), constitute a heterogeneous group of disorders originating from the blood and hematopoietic system. 1–3 Recent advances in antineoplastic therapies and earlier detection methods have significantly improved long-term survival rates among patients with these malignancies. However, an increasing number of survivors are developing second primary cancers (SPCs), defined as newly diagnosed, histologically distinct malignant tumors identified either concurrently (within 6 months) or subsequently (after 6 months) to the initial hematologic malignancy, excluding cases of metastatic disease and local recurrence. 4–6 The emergence of SPCs is influenced by a complex interplay of germline genetic susceptibility, therapy-induced cellular damage, environmental exposures, and remodeling of the tumor microenvironment. Notably, the risk of developing SPCs appears to be higher in survivors of hematologic malignancies compared to those with solid tumors. Research on SPCs following hematologic malignancies remains fragmented, lacking standardized diagnostic criteria and consensus-based management strategies in clinical practice. This narrative review systematically synthesizes the current evidence on the epidemiology, pathogenic mechanisms, and clinical management of SPCs after hematologic malignancies, aiming to provide a comprehensive reference for clinical practice and future research. Epidemiology: a rising tide after the storm Survivors of hematologic malignancies exhibit a significantly increased risk of SPCs compared to the general population, with standardized incidence ratios (SIRs) ranging from 1.27 to 2.60, indicating a 10–14% heightened incidence risk ( Table 1 ). 4 , 7 , 8 Population-based studies primarily provide broad risk estimates and incidence trends, whereas treatment-based cohorts enable a more precise evaluation of therapy-related carcinogenesis and dose–response associations between modalities such as radiotherapy, hematopoietic stem cell transplantation (HSCT), and chimeric antigen receptor T-cell (CAR-T) therapy. Integrating both perspectives is essential for comprehensive risk modeling. The extent of SPC risk is influenced by several factors, including disease subtype, age at diagnosis, and treatment era. Among hematologic malignancies, survivors of childhood non-Hodgkin lymphoma (NHL), mycosis fungoides (MF), and Hodgkin lymphoma (HL) represent the highest-risk groups. 9–11 While those with chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML) face a comparatively lower risk. 12–14 Notably, pediatric NHL survivors have reported an SIR of 19.80 (95% CI, 14.50–26.50) for any SPC when compared to age-matched peers.15 The phenotypes of SPCs vary according to age and treatment modalities. The most prevalent SPCs include therapy-related myeloid neoplasms (t-MN) and solid tumors affecting the thyroid, breast, and skin. 15 , 16 Pediatric survivors demonstrate a disproportionately high burden of SPCs compared to adults, primarily due to the increased sensitivity of developing hematopoietic and somatic tissues to cytotoxic therapies, as well as extended survival periods that allow for latent neoplastic progression. 17 Furthermore, the spectrum of SPCs has evolved in the contemporary treatment era, characterized by the introduction of CAR-T therapy and molecularly targeted agents. This evolution is evidenced by a decline in the incidence of t-MN, alongside a relative increase in solid tumors associated with chronic immune dysregulation. 18–20 Table 1. Incidence of SPCs in patients with hematological malignancies. Cancer type Registry Study period Patients (n) SIR (95% CI) PMID Multiple Myeloma SEER-9 (USA) 1973–2008 2021 1.07 (0.97–1.18) 25192415 11 Multiple Myeloma Swedish Cancer Registry 1958–1996 8656 2.19 (1.74–2.71) 11592772 15 Mycosis Fungoides SEER-18 (USA) 2000–2015 6742 10.15 (9.29–11.07) 31374302 10 Childhood NHL BFM Registry (Germany) 1981–2010 3590 19.80 (14.50–26.50) 32299903 17 Hodgkin Lymphoma SEER (USA) 2000–2020 36497 3.76 (2.67–5.30) 40406264 16 Hodgkin Lymphoma Netherlands 1965–2000 3905 4.60 (4.30–4.90) 26699166 8 Chronic Myeloid Leukemia SEER (USA) 2002–2014 9200 1.30 (1.20–1.40) 29456888 14 Chronic Lymphocytic Leukemia SEER (USA) 1973–2015 38754 1.20 (1.17–1.23) 31570695 13 Chronic Lymphocytic Leukemia Netherlands Cancer Registry 1989–2019 24815 1.63 (1.59–1.68) 36635262 12 Open in a new tab Note: All SIRs were age- and sex-adjusted to the general population unless otherwise specified. SIR = standardized incidence ratio; CI = confidence interval; NHL = non-Hodgkin lymphoma. High-risk populations for SPCs following hematologic neoplasms include survivors of pediatric NHL, MF, and HL. 8 , 15 , 17 In these cohorts, t-MN is more prevalent in children, while solid malignancies, such as lung, breast, and skin cancers, are more common among adults who have survived HL and MF. 7 , 8 , 17 Key modifiers of SPCs risk include cumulative radiotherapy dose, exposure to alkylating agents, age at initial treatment, and therapy-induced long-term immune dysfunction. The roots of risk: from aging to immunosuppression and inflammation The development of SPCs following hematologic malignancies arises from multifactorial interactions between host susceptibility and treatment- or disease-associated exposures. These factors converge to create a biological milieu conducive to malignant transformation. Based on current evidence, the principal contributors to SPCs risk can be categorized into four domains: cellular senescence associated with aging, metabolic dysregulation, oncogenic viral infections, and immune dysfunction accompanied by chronic inflammation ( Figure 1 ). The relative influence of each mechanism varies across patient subgroups and treatment regimens, highlighting the complexity of SPCs pathogenesis. Figure 1. Open in a new tab The “soil and seed” model of SPCs risk: aging, obesity, viral infection, and immune dysregulation jointly shape a pro-oncogenic microenvironment that predisposes to the development of second primary cancers. (A) Aging induces telomere shortening and impaired DNA repair capacity in hematopoietic stem cells (HSCs), contributing to genomic instability. (B) Obesity triggers adipocyte secretion of IL-6/TNF-α, which activates the NF-κB pathway and drives chronic inflammation. (C) Oncogenic viruses (EBV, HPV, HBV) integrate into the host genome, inducing TP53 mutations or RAS pathway activation, and ultimately leading to cellular malignant transformation. (D) Immunosuppression and chronic inflammation cause ROS accumulation, which impairs DNA repair function, exhausts CD8+ T cells, and thus abrogates immune surveillance. Aging Chronological aging is a well-established, non-modifiable risk factor for SPCs in both hematologic and solid tumors, exerting a particularly pronounced effect on survivors of hematologic malignancies whose hematopoietic and immune systems are already compromised. 21–23 Aging impairs genomic integrity and disrupts immune homeostasis synergistically. 24 Key hallmarks include functional defects in hematopoietic stem cells (HSCs), such as clonal expansion with diminished self-renewal capacity, myeloid lineage bias, telomere attrition, and aberrant epigenetic modifications. 21–23 , 25 Single-cell sequencing of HSCs from acute myeloid leukemia (AML) patients has revealed age-related epigenetic reprogramming, which downregulates essential differentiation genes and enriches a preleukemic HSC reservoir predisposed to malignant transformation. 23 , 26 This phenomenon correlates with higher rates of myeloid SPCs in older adults. 5 , 23 , 27 Concurrently, immunosenescence undermines antitumor surveillance, allowing incipient malignant clones to evade immune detection. 27 , 28 Obesity and metabolic disorders Obesity and metabolic dysregulation are closely associated with an increased risk of SPCs among survivors of hematologic neoplasms, mediated through hormonal, inflammatory, and immunological pathways. 29 , 30 A large prospective cohort study demonstrated that each 5 kg/m 2 increment in body mass index (BMI) at the time of cancer diagnosis was linked to a 13% increase in SPCs incidence. 30 Adipocyte hypertrophy induces local hypoxia, which promotes macrophage infiltration and creates a chronic, low-grade inflammatory state characterized by elevated levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). These cytokines contribute to DNA damage, proliferative signaling, and angiogenesis. 30–32 Preclinical models suggest that this inflammatory microenvironment upregulates immune checkpoint ligands, such as programmed death-ligand 1 (PD-L1), leading to CD8+ cytotoxic T-lymphocyte exhaustion and impaired immunoediting, thereby facilitating tumor cell expansion. 33–35 Viral infections Oncogenic viruses are recognized as common risk factors for SPCs in both hematologic and solid malignancies, particularly affecting individuals with pre-existing immune dysfunction. 36 Mendelian randomization studies have indicated that patients with oropharyngeal carcinoma, likely associated with human papillomavirus (HPV) infection, have an 18% increased risk of developing NHL. 37 Pathogens such as Helicobacter pylori, hepatitis B virus (HBV), hepatitis C virus (HCV), Epstein–Barr virus (EBV), HPV, and human immunodeficiency virus (HIV) are well-established etiological agents for gastric cancer, hepatocellular carcinoma, and hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma, and Burkitt lymphoma. 36 , 38 , 39 This underscores the shared viral oncogenesis that contributes to both primary and second cancers. Immunosuppression and inflammation Persistent immunosuppression and chronic inflammation are critical factors in the pathogenesis of SPCs, as they compromise the body’s natural antitumor defenses. Immune dysregulation is intrinsic to hematologic malignancies and may be exacerbated by therapeutic interventions, resulting in enduring effects that increase the risk of SPCs. 33 , 40 , 41 Survivors of DLBCL exhibit a 17.6-fold higher incidence of infections, autoimmune disorders, and immune deficiencies compared to survivors of other cancers. Elevated baseline CD8+ T-cell counts have been linked to a lower incidence of SPCs. 42 , 43 Within the tumor microenvironment, immunosuppression is mediated by transforming growth factor-β (TGF-β) and interleukin-10 (IL-10), which inhibit effector immune responses and promote the survival of malignant cells. Oxidative stress leads to the generation of reactive oxygen species (ROS) and pro-inflammatory cytokines, such as TNF-α and IL-6, which result in DNA repair defects and accelerated telomere shortening, thereby contributing to genomic instability. 33 , 40 Preclinical studies indicate that HSCs with mutations in DNMT3A , in a preleukemic state, can acquire secondary oncogenic mutations – such as FLT3 , NPM1 , and IDH1 –in response to inflammatory stimuli, thereby driving malignant transformation. 35 , 44 Collectively, these findings underscore the crucial role of impaired immune surveillance and chronic inflammation in the development of aggressive SPCs among survivors of hematologic malignancies. Mechanisms underlying SPCs pathogenesis in hematologic malignancy survivors The pathogenesis of SPCs following hematologic malignancies is a dynamic and multistage process driven by the interplay of germline susceptibility, therapy-induced genotoxicity, remodeling of the tumor microenvironment (TME), and effects mediated by circulating cell-free DNA (cfDNA) ( Figure 2 ). Figure 2. Open in a new tab Mechanisms underlying SPCs pathogenesis in hematologic malignancy survivors. (A) Genetic predisposition: Germline variants in TP53 , CHEK2 , BRCA1 , DDX41 , and low-penetrance SNPs establish a foundational risk context by abrogating DNA damage repair, cell-cycle control, and apoptosis pathways. Aberrant activation of the RAS signaling cascade further facilitates cross-lineage carcinogenesis. (B) Therapy-related factors: Radiotherapy, chemotherapy, and CAR-T cell therapy induce collateral genotoxic damage. Off-target radiation and cytotoxic agents cause DNA single-strand breaks and cellular senescence, while concurrently activating cancer-associated fibroblasts (CAFs) that remodel the bone marrow niche through proinflammatory cytokine secretion and metabolic reprogramming. (C) Tumor microenvironment remodeling: the therapy-altered niche and damaged stromal cells, secretes various factors such as TGF-β1, TNF-α and IL-6. These factors further promote the survival and clonal dominance of selected mutant hematopoietic stem and progenitor cells (HSPCs), thereby establishing a self-reinforcing pro-oncogenic loop. (D) cfDNA: Oncogenic cfDNA released from the first primary cancers can be internalized by recipient cells, potentially disrupting DNA damage response pathways and promoting malignant transformation at distant sites. Genetic predisposition Germline variants establish a foundational risk context for the development of SPCs. Singhal et al. reported that 19% of patients with lymphoid malignancies and concomitant primary cancers harbor pathogenic germline mutations, most frequently in CHEK2 , BRCA1 , DDX41 , and TP53 . 45–47 Loss of TP53 function abrogates critical tumor-suppressive pathways, including DNA damage repair, cell-cycle control, and apoptosis, thereby promoting the survival of genomically damaged clones. 48 , 49 In mediastinal non-seminomatous germ cell tumors co-occurring with hematologic neoplasms, TP53 mutations are found in up to 91% of cases, often concurrent with RAS pathway activation, which facilitates cross-lineage carcinogenesis. 50 Genome-wide association studies (GWAS) have implicated low-penetrance single-nucleotide polymorphisms (SNPs) (e.g., rs191064896, rs535484207, rs139586367) in polygenic susceptibility to SPCs among survivors of hematologic malignancies. 51 , 52 However, this hypothesis is constrained by heterogeneity in study populations and genotyping methods, necessitating further validation through large-sample, multicenter cohort studies. Treatment-related factors Advancements in chemotherapy, HSCT, immunotherapy, and targeted agents have significantly improved patient outcomes; however, they also induce collateral damage that increases the risk of SPCs. 53 , 54 For instance, radiotherapy elevates the risk of secondary lung cancer in patients with HL by a factor of 8.70 (95% CI: 7.90–9.60). Additionally, alkylating agents, such as melphalan, are implicated in approximately 89% of therapy-related acute myeloid leukemia (t-AML) cases among patients with multiple myeloma. 8 Radiotherapy: inducing genomic instability and immune evasion Radiotherapy elevates the risk of SPCs through mechanisms including direct DNA damage, induction of cellular senescence, and systemic immunosuppression ( Figure 3 ). 55–57 Off-target ionizing radiation leads to the formation of single-strand breaks (SSBs) and depletes intracellular NAD+ pools, thereby impairing the PARP1 -mediated repair of these SSBs. 58 The accumulation of unrepaired lesions drives cells into a senescent state characterized by G0/G1 arrest, upregulation of p16 and p21 , increased β-galactosidase activity, and the development of a secretory phenotype. Senescent cells may subsequently escape growth arrest via a process known as Post-Senescence Neoplastic Escape (PSNE), exhibiting matrix metalloproteinase (MMP) activity and invasive behavior. 59–62 During PSNE, previously senescent cells can reacquire proliferative capacity, accompanied by genomic instability, epigenetic alterations, and activation of oncogenic signaling pathways. 56–59 These transformed cells may contribute to malignant transformation in surrounding tissues, thereby potentially increasing the risk of SPC development following radiotherapy. Figure 3. Open in a new tab Schematic diagram of the mechanism of SPCs induced by radiotherapy and chemotherapy. Illustration: a multi-step carcinogenic process involving: (1) DNA damage (e.g., single-strand breaks in normal cells); (2) accumulation of senescent cells (characterized by p16 / p21 upregulation and SASP, with potential for post-senescence neoplastic escape); (3) immunosuppression (e.g., lymphopenia, M2 macrophage polarization, impaired immune surveillance); (4) tumor microenvironment remodeling (e.g., CAF activation, pro-inflammatory cytokine secretion, lactate and metabolite release); ultimately leading to SPCs development. Concurrently, radiotherapy-induced lymphopenia and M2 macrophage polarization hinder the immune-mediated clearance of premalignant clones and may reactivate oncogenic viruses such as EBV in NHL. 60 , 62 Telomere shortening and reduced telomerase activity initiate breakage-fusion-bridge cycles, which promote chromosomal rearrangements and persistent genomic instability. 62 Most evidence derives from retrospective series with heterogeneous dosing and follow-up; therefore, prospective studies are required to delineate the dose-dependent risks of SPCs. 55 Chemotherapy: direct mutagenesis and microenvironment reprogramming Alkylating agents and topoisomerase II inhibitors are potent mutagens that directly damage DNA. 63 , 64 Melphalan induces interstrand crosslinks, whereas etoposide causes double-strand breaks and KMT2A ( 11q23 ) translocations. 63 Cytotoxic agents also remodel the bone marrow niche by damaging mesenchymal stromal cells and inducing oxidative stress that activates HIF , NF-κB , and STAT3 pathways in stromal elements. 65 Metabolic reprogramming generates lactate, free fatty acids, and glutamine to fuel tumor growth. 66–69 Cancer-associated fibroblasts (CAFs) secrete proinflammatory cytokines (IL-6, IL-8), further promoting malignant transformation. 65 , 68 Both radiotherapy and chemotherapy impair T-cell and natural killer (NK)-cell function 70 , 71 ; platinum compounds reduce lymphocyte counts, undermining immunosurveillance and enabling viral reactivation. 6 , 54 , 63 Anti-angiogenic therapies (e.g., bevacizumab) may exacerbate hypoxia-driven tumorigenesis, and combination regimens can potentiate DNA damage-driven carcinogenesis. 72 CAR-T therapy–associated mechanisms CAR-T therapy has significantly transformed the treatment landscape for refractory hematologic neoplasms; however, it carries a measurable risk of SPCs. 73–75 According to a 2024 report from the Center for International Blood and Marrow Transplant Research (CIBMTR), the cumulative incidence of SPCs was 4.30% (485 out of 11,345) in patients following CAR-T therapy, with a median follow-up of 13 months. 20 This absolute risk is not significantly higher than the baseline SPCs risk observed in heavily pretreated hematologic neoplasm populations and is comparable to the SPCs risk associated with HSCT or conventional salvage chemotherapy. 20 , 76 While CAR-T therapy may further exacerbate immune dysregulation in patients and promote the progression of pre-existing precancerous lesions to SPCs, there is currently no clinical evidence to suggest that CAR-T therapy directly induces the development of SPCs. 20 , 77 , 78 The mechanisms underlying these adverse events can be categorized into three key aspects ( Figure 4 ). (1) Insertional mutagenesis: The random integration of CAR transgenes via lentiviral vectors near oncogenes (e.g., MYC ) or within tumor suppressor genes (e.g., TP53 ) may lead to the malignant transformation of T-cells, resulting in the emergence of CAR-positive SPCs. This hypothesis is primarily supported by case reports and preclinical studies, with no large-scale clinical evidence confirming a causal relationship between CAR-T-associated insertional mutagenesis and SPCs. (2) Myeloid transformation: Pre-existing clonal hematopoiesis of indeterminate potential (CHIP), particularly in the presence of TP53 or TET2 mutations, confers resistance to lymphodepleting chemotherapy prior to CAR-T therapy (e.g., fludarabine/cyclophosphamide), thereby facilitating the selective expansion of CHIP clones and progression to myeloid SPCs (e.g., MDS, AML). (3) Immune dysregulation: Lymphodepleting chemotherapy, in conjunction with the antigen-restricted function of CAR-T cells, depletes CD8+ cytotoxic T lymphocytes, impairs antitumor surveillance, and allows solid tumor cells to evade immune control. 20 , 77–81 However, most studies examining CAR-T-associated SPCs have a follow-up duration of less than 2 y; thus, the long-term risk of SPCs (≥5 y) following CAR-T therapy remains unknown due to the relatively short clinical application history of this therapeutic approach. 20 , 77 , 82 Figure 4. Open in a new tab Mechanisms of SPCs after CAR-T therapy. (A) Insertional mutagenesis: Lentiviral transduction results in random integration of car transgenes, which may induce malignant transformation of T cells. (B) Myeloid transformation: pre-existing clonal hematopoiesis of indeterminate potential (chip) (e.g., TP53 / TET2 -mutated clones) undergo expansion after lymphodepleting chemotherapy prior to CAR-T therapy, and subsequently progress to myeloid SPCs (e.g., MDS/AML). (C) Immune dysregulation promoting solid tumorigenesis: lymphodepletion and antigen-restricted CAR-T cell activity impair anti-tumor immune responses, allowing solid tumor cells to escape immune surveillance and ultimately leading to SPCs formation. Tumor microenvironment remodeling Inflammation and cytotoxic therapy synergistically reshape the hematopoietic ecosystem, facilitating the emergence of CHIP through cumulative genotoxic injury and replicative stress. Somatic mutations in DNMT3A , TET2 , and ASXL1 confer enhanced fitness to hematopoietic stem and progenitor cells (HSPCs) under conditions of oxidative damage and chronic inflammation. 83–85 However, the transition from benign CHIP to overt t-MNs or secondary solid cancers necessitates additional selective pressures arising directly from the therapeutic environment. 86 , 87 Under sustained genotoxic stress induced by chemotherapy and radiotherapy, the bone marrow niche experiences profound molecular and cellular reprogramming, shifting toward a pro-inflammatory and immunosuppressive phenotype characterized by elevated levels of IL-6, TNF-α, TGF-β1, and reactive ROS. 86 , 87 This remodeled microenvironment functions not merely as a passive byproduct of therapy, but as an active selective engine that preferentially expands pre-leukemic CHIP clones through several convergent mechanisms. (1) Dysregulation of the DNA Damage Response (DDR): Clones with mutations in TP53 and PPM1D exhibit impaired apoptosis following double-strand breaks induced by alkylating agents or ionizing radiation, thereby gaining a competitive advantage over wild-type hematopoietic stem and progenitor cells (HSPCs). Notably, PPM1D mutations are enriched under cytotoxic stress by suppressing p53 -dependent cell-cycle arrest and apoptosis, which facilitates post-treatment clonal expansion and dominance. 88–90 (2) Hijacking of Inflammatory Signaling: TET2 -mutated HSPCs show hyperactivation of the NLRP3 inflammasome and exaggerated secretion of IL-1β upon inflammatory stimulation, establishing a self-reinforcing circuit in which mutant clones both amplify and exploit the inflammatory environment. Concurrently, IL-6 and TNF-α released from therapy-activated stromal cells and macrophages engage JAK-STAT and NF-κB signaling pathways in DNMT3A -mutant clones, promoting their self-renewal and myeloid lineage bias while suppressing normal hematopoiesis. 91–93 (3) Metabolic Adaptation: Cytotoxic therapy induces persistent oxidative stress that favors clones with enhanced antioxidant defenses. Mutations in ASXL1 and IDH1/2 confer resistance to oxidative injury through mitochondrial reprogramming and epigenetic modulation, enabling the survival of damaged HSPCs that would otherwise be cleared. 84 , 94 This therapy-driven clonal selection is reinforced by niche components that sustain a pro-oncogenic microenvironment. Cancer-associated fibroblasts (CAFs), therapy-damaged mesenchymal stromal cells, and adipose-derived stromal elements secrete stem cell factor (SCF), insulin-like growth factor-1 (IGF-1), a range of pro-inflammatory cytokines, and extracellular matrix proteins. 95–97 Together, these elements establish a protective niche that promotes clonal persistence and confers resistance to further therapy. Importantly, the inflammatory network generated by CHIP clones extends beyond the marrow compartment; circulating IL-6, IL-1β, and other mediators infiltrate peripheral tissues, inducing immune checkpoint upregulation, angiogenesis, and stromal activation. 95–99 These systemic alterations foster a tumor-permissive environment that is conducive to the development of secondary solid malignancies. In summary, the tumor microenvironment transitions from a passive structural scaffold to an active architect of clonal evolution, wherein therapy-induced inflammation, oxidative stress, and DNA damage collaboratively redefine the selective landscape. This integrated cascade mechanistically links cytotoxic treatment exposure with the malignant transformation of pre-existing CHIP clones into therapy-related myeloid neoplasms and secondary primary cancers. Circulating cell-free DNA Emerging preclinical data suggest that cfDNA bearing oncogenic mutations can be internalized by recipient cells, disrupting DNA damage response pathways. 100–104 Although this mechanism remains speculative in clinical contexts, cfDNA represents a potential biomarker and therapeutic target for SPCs risk stratification. 100 , 101 Further investigation is warranted to confirm its oncogenic role in vivo and to explore its utility in personalized survivorship surveillance. Clinical management and treatment strategies With the increasing awareness of SPCs risk, it is essential to integrate prevention and risk-management strategies throughout the care continuum for survivors of hematologic malignancies. These strategies encompass risk-adapted modifications of initial treatment regimens, enhanced surveillance prior to SPCs diagnosis, and coordinated management by multidisciplinary teams (MDTs) following the onset of SPCs. Treatment adjustment and risk mitigation While CAR-T therapy has significantly advanced the treatment of relapsed or refractory hematologic malignancies, its association with SPCs underscores the need for vigilant risk mitigation strategies. 19 , 78 Recommended interventions include regular dermatologic examinations for the surveillance of non-melanoma skin cancers, 78 , 105 periodic hematologic assessments such as complete blood counts (CBCs), and comprehensive clinical evaluations, especially for patients with CH-related mutations like TP53 and TET2 . 106 , 107 Furthermore, age- and risk-adapted cancer screenings should be conducted in accordance with established guidelines for both the general population and cancer survivors. Additionally, monitoring of predictive biomarkers is essential to inform future risk-stratified surveillance protocols. 19 , 106 Surveillance and early detection Given the elevated risk of SPCs in survivors of hematologic malignancies and the well-documented benefits of early detection, structured surveillance has become a cornerstone of survivorship care. 101 , 108 However, there is a notable absence of evidence-based, consensus-driven screening guidelines for SPCs tailored specifically to this population. Current practices rely on screening recommendations designed for the general population and survivors of solid tumors, with individual modifications based on prior treatment exposures (e.g., radiation fields, alkylating agents), genetic predisposition, and modifiable risk factors. 4 , 37 An optimal monitoring strategy should integrate: (1) standard-of-care screening tailored to therapy-related risks (e.g., breast magnetic resonance imaging [MRI] for female Hodgkin lymphoma survivors who received prior chest irradiation) 109 , 110 ; (2) heightened clinical vigilance for relevant signs and symptoms; and (3) the incorporation of emerging modalities, such as circulating tumor DNA (ctDNA) analysis, as supporting evidence becomes available. 100 , 101 The objective is to transition from uniform surveillance protocols to personalized, risk-adapted strategies that maximize early detection of SPCs while minimizing unnecessary procedures and patient burden. 4 , 111 Multidisciplinary team management No standardized algorithm exists for SPCs arising from hematologic malignancies; therefore, optimal clinical decision-making requires an MDT approach. An effective MDT typically comprises hematologists, medical oncologists, radiation oncologists, surgical oncologists (as dictated by the subtype of SPCs), pathologists, radiologists, and supportive care specialists. 111 , 112 The MDT integrates critical information, including the status of the primary malignancy, the stage of SPCs, histology, molecular profile, cumulative treatment history, comorbidities, organ function, and performance status (assessed via comprehensive geriatric assessment in elderly patients). This information is crucial for prioritizing interventions, generally addressing the malignancy with the most immediate life-threatening risk, and for developing individualized treatment plans that maximize therapeutic benefits while minimizing cumulative toxicity. 111–114 Future directions: investigational strategies and technologies Investigational approaches for risk mitigation Preclinical and early-phase clinical research are investigating targeted interventions aimed at disrupting key pathways involved in therapy-related carcinogenesis. The strategies under examination focus on enhancing DNA repair mechanisms and eliminating pro-oncogenic cellular states that arise from cytotoxic treatments. For instance, preclinical models have shown that replenishing intracellular pools of nicotinamide adenine dinucleotide (NAD + ) through nicotinamide mononucleotide (NMN) facilitates poly (ADP-ribose) polymerase (PARP)-mediated DNA repair following fractionated radiotherapy. 115–117 Similarly, senolytic regimens, such as dasatinib in combination with quercetin, selectively eliminate senescent cells, thereby addressing a proposed precursor state for SPCs. 118 , 119 Although these approaches are mechanistically intriguing, they have not yet been validated in large-scale, randomized clinical trials to confirm their efficacy and safety for the prevention of SPCs. Emerging monitoring technologies Advances in minimally invasive monitoring hold promise for the earlier detection of SPCs and dynamic risk stratification. Liquid biopsy, particularly the analysis of ctDNA through next-generation sequencing (NGS), allows for the sensitive identification of tumor-specific genetic and epigenetic alterations, often providing a diagnostic advantage over conventional imaging modalities. 103 , 120 , 121 While ctDNA assays are well established in solid tumors, their utility in detecting molecular residual disease and early relapse in survivors of hematologic malignancies remains an active area of research. 121 , 122 Recent advances in multi-omics technologies-including genomics, epigenomics, transcriptomics, proteomics, and metabolomics-have enabled a comprehensive molecular dissection of therapy-related carcinogenesis and clonal evolution in survivors of hematologic malignancies. Integrated multi-omics studies now facilitate the identification of convergent pathways that link therapy-induced genotoxic stress to the emergence of secondary tumors. In the context of acute myeloid leukemia (AML), for instance, integrated proteogenomic analyses have shed light on the therapy-adaptive reprogramming of DNA repair and redox signaling networks, thereby providing a translational foundation for precision monitoring in survivors of SPCs. 123 Furthermore, pan-genomic frameworks have broadened our understanding of functional genome architecture and population-level genetic susceptibility to secondary malignancies. 124 These integrative models assist in delineating high-risk genotypes and informing target-specific surveillance pipelines. Beyond circulating ctDNA, emerging biomarker discoveries underscore molecular targets of pan-cancer significance. For example, ZNF165, a zinc finger transcriptional regulator aberrantly expressed in various malignancies, is recognized for its prognostic potential across different tumor types. 125 Similarly, tumor heterogeneity markers derived from single-cell multi-omics profiling enable the dynamic tracking of oncogenic clone evolution and therapeutic resistance. 126 Ultimately, these biomarkers may complement ctDNA assays to enhance precision risk stratification and the early detection of SPCs. Novel therapeutic strategies The management of established SPCs follows standard oncologic principles, including surgical resection, radiotherapy, chemotherapy, and molecularly targeted therapies. These approaches are tailored to the tumor’s histology, stage, and molecular profile, while also considering prior treatment exposures. 113 , 127 Emerging therapeutic modalities currently under clinical evaluation for the treatment of SPCs include antibody-drug conjugates (ADCs), which are engineered to selectively deliver cytotoxic payloads to tumor cells that express specific surface antigens. 128–130 Additionally, therapeutic cancer vaccines and adoptive immunotherapies are designed to generate antitumor immune responses against shared tumor-associated antigens or patient-specific neoantigens. Small-molecule inhibitors targeting oncogenic driver mutations, such as RAS and TP53 , are also being investigated. 131–133 Furthermore, modulators of the tumor microenvironment, which address stromal components like cancer-associated fibroblasts, present a novel strategy to disrupt protumoral niches and enhance treatment efficacy. 134 , 135 The optimal selection and sequencing of these therapeutic modalities within a MDT framework remain central to the individualized management of SPCs. The role of the microbiome in modulating oncogenic signaling and systemic inflammation within the tumor microenvironment is increasingly recognized. Dysbiosis-driven alterations in immune tone and metabolic outputs can create pro-tumoral niches that are conducive to the development of SPCs. 136 Concurrently, therapeutic nanomaterials designed for microenvironmental regulation – such as immune-modulatory nanoparticles and redox-sensitive nanosystems – show promise in reprogramming stromal interactions and mitigating therapy-related carcinogenesis. 144 Collectively, these integrated approaches are reshaping the conceptual framework for monitoring SPCs, aligning mechanism-based insights with novel drug discovery paradigms. Conclusion SPCs present a significant long-term survivorship challenge for patients treated for hematologic malignancies. The pathogenesis of SPCs arises from a multifactorial interplay of various factors, with the cumulative treatment burden identified as the primary modifiable risk factor for their development. Current clinical management adheres to a risk-adapted framework led by a MDT, emphasizing the minimization of iatrogenic carcinogenic insults and the implementation of individualized early surveillance protocols. Despite these advancements, critical knowledge gaps remain: there are currently no disease-specific SPCs screening guidelines tailored for hematologic cancer survivors, and validated integrative risk prediction models that combine genetic profiles, prior therapeutic exposures, and clinical parameters are still lacking. Future research should prioritize the development of personalized risk-stratification tools, mechanistic studies that elucidate the ontogeny of therapy-induced SPCs, and the formulation of evidence-based MDT practice guidelines to translate proactive prevention into routine care. Furthermore, most emerging strategies for SPCs risk reduction and novel surveillance technologies are currently confined to preclinical or early-phase clinical evaluations. Robust validation in large prospective cohorts and dedicated translational investigations are essential before these approaches can be widely adopted in clinical practice. Addressing these gaps will be crucial for improving long-term outcomes and quality of life for survivors of hematologic malignancies. This review is limited by the heterogeneity of primary data sources, variation in follow-up durations, and the scarcity of prospective clinical trials validating SPCs-specific surveillance. For clinicians, actionable steps include adopting individualized screening protocols aligned with therapeutic exposures and genetic predispositions, and integrating molecular surveillance tools – such as ctDNA and multi-omics panels – into survivorship programs. Researchers should prioritize large-scale longitudinal studies exploring therapy-induced genomic instability and develop standardized risk prediction models linking treatment history, omics signatures, and real-world outcomes. Robust multi-center collaborations will be vital to translate these insights into precision survivorship care. 137–143 Acknowledgments We would like to thank the fruitfull discussions of all members of Dr. Qiong Wang’s research laboratory. Biography Qiong Wang , MD, PhD, is Chief Physician in the Clinical Laboratory of Wuxi People’s Hospital, China. Holding a Ph.D. in Laboratory Diagnostics from Nanjing Medical University, she has 16 y of clinical and research experience. Her work focuses on asthma pathogenesis and she leads quality-control initiatives that bridge lab data with bedside care. Funding Statement This study was supported by Wuxi City’s “Double Hundred” Young and Middle aged Medical and Health Top Talents [BJ2023004]; Jiangsu Province Preventive Medicine General Project [Ym2023008]; Reserve Discipline Leader of Wuxi People’s Hospital [2024-YZ-HBDTR-WQ-2024]. Disclosure statement No potential conflict of interest was reported by the author(s). Data availability statement Data sharing is not applicable to this article as no new data were created or analyzed in this study. References 1. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A.. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10–18. doi: 10.3322/caac.21871. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 2. Pan T, Zhang J, Wang X, Song Y. Global burden and trends of hematologic malignancies based on Global Cancer Observatory 2022 and Global Burden of Disease 2021. Exp Hematol Oncol. 2025;14(1):98. doi: 10.1186/s40164-025-00684-x. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 3. Jabbour E, Short NJ, Jain N, Haddad FG, Welch MA, Ravandi F, Kantarjian H. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. J Hematol Oncol. 2023;16(1):22–19. doi: 10.1186/s13045-023-01409-5. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 4. Zeng M, Lin A, Jiang A, Qiu Z, Zhang H, Chen S, Xu M, Liu Z, Cheng Q, Zhang J, et al. Decoding the mechanisms behind second primary cancers. J Transl Med. 2025;23(1):115. doi: 10.1186/s12967-025-06151-9. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 5. Yang H, Liu D, Qiu L, Wang R, Zhang C, Yu D, Zhong Q, Yuki N, Song Z, Zhu T, et al. Reprogramming cellular senescence and aging clocks for advanced cancer immunotherapy. Mol Cancer. 2025;24(1):237. doi: 10.1186/s12943-025-02459-8. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 6. Zhang Y, Naderi YP, Zhang H, Wang SY, Li Z, Gu B, Lee D-J, Zhang Z, Ploumakis A, Shi M, et al. Tumor editing suppresses innate and adaptive antitumor immunity and is reversed by inhibiting DNA methylation. Nat Immunol. 2024;25(10):1858–1870. doi: 10.1038/s41590-024-01932-8. [ DOI ] [ PubMed ] [ Google Scholar ] 7. Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T, Omlin A. Multiple primary tumours: challenges and approaches, a review. ESMO Open. 2017;2(2):e000172. doi: 10.1136/esmoopen-2017-000172. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 8. Schaapveld M, Aleman BM, van Eggermond AM, Janus CPM, Krol ADG, van der Maazen RWM, Roesink J, Raemaekers JMM, de Boer JP, Zijlstra JM, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med. 2015;373(26):2499–2511. doi: 10.1056/NEJMoa1505949. [ DOI ] [ PubMed ] [ Google Scholar ] 9. Atci T, Ak DY, Baykal C. Evaluation of secondary malignancies in a large series of mycosis fungoides. An Bras Dermatol. 2024;99(3):370–379. doi: 10.1016/j.abd.2023.06.004. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 10. Goyal A, O’Leary D, Goyal K, Rubin N, Bohjanen K, Hordinsky M, Chen ST, Pongas G, Duncan LM, Lazaryan A. Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: a surveillance, epidemiology, and end results analysis. J Am Acad Dermatol. 2020;83(2):404–411. doi: 10.1016/j.jaad.2019.07.075. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 11. Ailawadhi S, Swaika A, Razavi P, Yang D, Chanan-Khan A. Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups. Blood Cancer J. 2014;4(9):e243. doi: 10.1038/bcj.2014.63. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 12. van der Straten L, Levin MD, Dinnessen M, Visser O, Posthuma EFM, Doorduijn JK, Langerak AW, Kater AP, Dinmohamed AG. Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019. Blood Cancer J. 2023;13(1):15. doi: 10.1038/s41408-023-00784-z. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 13. Kumar V, Ailawadhi S, Bojanini L, Mehta A, Biswas S, Sher T, Roy V, Vishnu P, Marin-Acevedo J, Alegria VR, et al. Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer J. 2019;9(10):75. doi: 10.1038/s41408-019-0237-1. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 14. Kumar V, Garg M, Chaudhary N, Chandra AB. An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States. PeerJ. 2018;6:e4342. doi: 10.7717/peerj.4342. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 15. Dong C, Hemminki K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958–1996: a search for common mechanisms. Br J Cancer. 2001;85(7):997–1005. doi: 10.1054/bjoc.2001.1998. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 16. Lin F, Liu D, Huang T, Luo Y. Impact of secondary hematologic malignancies on prognosis of Hodgkin’s lymphoma survivors. Front Oncol. 2025;15:1566063. doi: 10.3389/fonc.2025.1566063. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 17. Moser O, Zimmermann M, Meyer U, Klapper W, Oschlies I, Schrappe M, Attarbaschi A, Mann G, Niggli F, Spix C, et al. Second malignancies after treatment of childhood non-Hodgkin lymphoma: a report of the Berlin-Frankfurt-Muenster study group. Haematologica. 2021;106(5):1390–1400. doi: 10.3324/haematol.2019.244780. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 18. Avigan ZM, Catlett J, Bodnar S, Pan D, Aleman A, Sheng T, Moshier E, Rossi AC, Richard S, Kaur G, et al. Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy. Clin Cancer Res. 2025;31(20):4333–4344. doi: 10.1158/1078-0432.CCR-25-1587. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 19. Umyarova E, Pei C, Pellegrino W, Zhao Q, Sharma N, Benson D, Cottini F, Bezerra E, Brammer J, Bumma N, et al. Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies. J Hematol Oncol. 2025;18(1):30. doi: 10.1186/s13045-025-01676-4. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 20. Verdun N, Marks P. Secondary cancers after chimeric antigen receptor T-cell therapy. N Engl J Med. 2024;390(7):584–586. doi: 10.1056/NEJMp2400209. [ DOI ] [ PubMed ] [ Google Scholar ] 21. Mitchell CA, Verovskaya EV, Calero-Nieto FJ, Olson OC, Swann JW, Wang X, Hérault A, Dellorusso PV, Zhang SY, Svendsen AF, et al. Stromal niche inflammation mediated by IL-1 signalling is a targetable driver of haematopoietic ageing. Nat Cell Biol. 2023;25(1):30–41. doi: 10.1038/s41556-022-01053-0. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 22. Mietsch M, Hinkel R. “Empowering” cardiac cells via stem cell derived mitochondrial transplantation- does age matter? Int J Mol Sci. 2021;22(4):1824. doi: 10.3390/ijms22041824. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 23. Adelman ER, Huang HT, Roisman A, Olsson A, Colaprico A, Qin T, Lindsley RC, Bejar R, Salomonis N, Grimes HL, et al. Aging human hematopoietic stem cells manifest profound epigenetic reprogramming of enhancers that may predispose to leukemia. Cancer Discov. 2019;9(8):1080–1101. doi: 10.1158/2159-8290.CD-18-1474. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 24. Ajoolabady A, Pratico D, Tang D, Zhou S, Franceschi C, Ren J. Immunosenescence and inflammaging: mechanisms and role in diseases. Ageing Res Rev. 2024;101:102540. doi: 10.1016/j.arr.2024.102540. [ DOI ] [ PubMed ] [ Google Scholar ] 25. Langseth OO, Myklebust TA, Johannesen TB, Hjertner O, Waage A. Patterns of previous and secondary malignancies in patients with multiple myeloma. Eur J Haematol. 2021;106(4):529–536. doi: 10.1111/ejh.13581. [ DOI ] [ PubMed ] [ Google Scholar ] 26. Salminen A. Cooperation between inhibitory immune checkpoints of senescent cells with immunosuppressive network to promote immunosenescence and the aging process. Ageing Res Rev. 2025;106:102694. doi: 10.1016/j.arr.2025.102694. [ DOI ] [ PubMed ] [ Google Scholar ] 27. Wang TW, Nakanishi M. Immune surveillance of senescence: potential application to age-related diseases. Trends Cell Biol. 2025;35(3):248–257. doi: 10.1016/j.tcb.2024.06.007. [ DOI ] [ PubMed ] [ Google Scholar ] 28. Shi H, Xiao M, Li Y, Liu X, Na J, Liang C, Hua J, Meng Q, Wei M, Wang W, et al. The role of senescence, its therapeutic relevance and clinical implications in the tumor microenvironment. Theranostics. 2025;15(16):8675–8703. doi: 10.7150/thno.112633. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 29. Mandic M, Safizadeh F, Sch Ttker B, Hoffmeister M, Brenner H. Association of childhood-to-adulthood body size change with cancer risk: UK Biobank prospective cohort. BMC Med. 2025;23(1):268. doi: 10.1186/s12916-025-04052-8. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 30. Bodelon C, Sung H, Mitchell EL, Deubler EL, Newton CC, Jemal A, Teras LR, Patel AV. Excess body weight and the risk of second primary cancers among cancer survivors. JAMA Netw Open. 2024;7(9):e2433132. doi: 10.1001/jamanetworkopen.2024.33132. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 31. Liu Q, Wei D, Hammar N, Yang Y, Feychting M, Zhang Z, Walldius G, Smedby KE, Fang F. Lipids, apolipoproteins, carbohydrates, and risk of hematological malignancies. Eur J Epidemiol. 2025;40(2):187–196. doi: 10.1007/s10654-025-01207-y. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 32. Tsilingiris D, Vallianou NG, Spyrou N, Kounatidis D, Christodoulatos GS, Karampela I, Dalamaga M. Obesity and leukemia: biological mechanisms, perspectives, and challenges. Curr Obes Rep. 2024;13(1):1–34. doi: 10.1007/s13679-023-00542-z. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 33. Saluja S, Bansal I, Bhardwaj R, Beg MS, Palanichamy JK. Inflammation as a driver of hematological malignancies. Front Oncol. 2024;14:1347402. doi: 10.3389/fonc.2024.1347402. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 34. Gold NM, Okeke MN, He Y. Involvement of inheritance in determining telomere length beyond environmental and lifestyle factors. Aging Dis. 2023;15(6):2470–2490. doi: 10.14336/AD.2023.1023. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 35. Rodriguez-Meira A, Norfo R, Wen S, Chédeville AL, Rahman H, O’Sullivan J, Wang G, Louka E, Kretzschmar WW, Paterson A, et al. Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution. Nat Genet. 2023;55(9):1531–1541. doi: 10.1038/s41588-023-01480-1. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 36. Xiao Q, Liu Y, Li T, Wang C, He S, Zhai L, Yang Z, Zhang X, Wu Y, Liu Y. Viral oncogenesis in cancer: from mechanisms to therapeutics. Signal Transduct Tar. 2025;10(1):151. doi: 10.1038/s41392-025-02197-9. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 37. Ruan X, Huang D, Zhan Y, Huang J, Huang J, Ng ATL, Tsu JHL, Na R. Risk of second primary cancers after a diagnosis of first primary cancer: a pan-cancer analysis and Mendelian randomization study. Elife. 2023;12:e86379. doi: 10.7554/eLife.86379. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 38. Zhan Z, Guo W, Li J, Wan X, Guo J, Bai O. Clinical features and prognosis of double primary malignant neoplasms in patients with non-Hodgkin lymphoma. Discov Oncol. 2023;14(1):54. doi: 10.1007/s12672-023-00667-6. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 39. Herr MM, Schonfeld SJ, Dores GM, Engels EA, Tucker MA, Curtis RE, Morton LM. Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes. Blood Adv. 2019;3(13):1961–1969. doi: 10.1182/bloodadvances.2019030924. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 40. Liang R, Qi X, Cai Q, Niu L, Huang X, Zhang D, Ling J, Wu Y, Chen Y, Yang P, et al. The role of NLRP3 inflammasome in aging and age-related diseases. Immun Ageing. 2024;21(1):14. doi: 10.1186/s12979-023-00395-z. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 41. Shalapour S, Karin M. Pas de deux: control of anti-tumor immunity by cancer-associated inflammation. Immunity. 2019;51(1):15–26. doi: 10.1016/j.immuni.2019.06.021. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 42. Bond DA, Huang Y, Fisher JL, Ruppert AS, Owen DH, Bertino EM, Rogers KA, Bhat SA, Grever MR, Jaglowski SM, et al. Second cancer incidence in CLL patients receiving BTK inhibitors. Leukemia. 2020;34(12):3197–3205. doi: 10.1038/s41375-020-0987-6. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 43. Shree T, Li Q, Glaser SL, Brunson A, Maecker HT, Haile RW, Levy R, Keegan THM. Impaired immune health in survivors of diffuse large B-cell lymphoma. J Clin Oncol. 2020;38(15):1664–1675. doi: 10.1200/JCO.19.01937. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 44. Yang X, Wong M, Ng RK. Aberrant DNA methylation in acute myeloid leukemia and its clinical implications. Int J Mol Sci. 2019;20(18):4576. doi: 10.3390/ijms20184576. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 45. Shah MV, Arber DA, Hiwase DK. TP53 -mutated myeloid neoplasms: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2025;100(Suppl 4):88–115. doi: 10.1002/ajh.27655. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 46. Sturgeon CM, Wagenblast E, Izzo F, Papapetrou EP. The crossroads of clonal evolution, differentiation hierarchy, and ontogeny in leukemia development. Blood Cancer Discov. 2025;6(2):94–109. doi: 10.1158/2643-3230.BCD-24-0235. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 47. Singhal D, Hahn CN, Feurstein S, Wee LYA, Moma L, Kutyna MM, Chhetri R, Eshraghi L, Schreiber AW, Feng J, et al. Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia. 2021;35(11):3245–3256. doi: 10.1038/s41375-021-01246-w. [ DOI ] [ PubMed ] [ Google Scholar ] 48. Rofes P, Castillo-Manzano C, Menendez M, Teulé Á, Iglesias S, Munté E, Ramos-Muntada M, Gómez C, Tornero E, Darder E, et al. TP53 germline testing and hereditary cancer: how somatic events and clinical criteria affect variant detection rate. Genome Med. 2025;17(1):3. doi: 10.1186/s13073-025-01429-5. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 49. Peltomaki P, Nystrom M, Mecklin JP, Seppala TT. Lynch syndrome genetics and clinical implications. Gastroenterology. 2023;164(5):783–799. doi: 10.1053/j.gastro.2022.08.058. [ DOI ] [ PubMed ] [ Google Scholar ] 50. Taylor J, Donoghue MT, Ho C, Petrova-Drus K, Al-Ahmadie HA, Funt SA, Zhang Y, Aypar U, Rao P, Chavan SS, et al. Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. J Clin Invest. 2020;130(12):6668–6676. doi: 10.1172/JCI139682. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 51. Sato G, Shirai Y, Namba S, Edahiro R, Sonehara K, Hata T, Uemura M, Yamanashi Y, Furukawa Y, Morisaki T, et al. Pan-cancer and cross-population genome-wide association studies dissect shared genetic backgrounds underlying carcinogenesis. Nat Commun. 2023;14(1):3671. doi: 10.1038/s41467-023-39136-7. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 52. Rashkin SR, Graff RE, Kachuri L, Thai KK, Alexeeff SE, Blatchins MA, Cavazos TB, Corley DA, Emami NC, Hoffman JD, et al. Pan-cancer study detects genetic risk variants and shared genetic basis in two large cohorts. Nat Commun. 2020;11(1):4423. doi: 10.1038/s41467-020-18246-6. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 53. Dee EC, Wu JF, Feliciano E, Jacomina LE, Yahalom J. Radiotherapy for haematological malignancies. Lancet Haematol. 2024;11(10):e721–e722. doi: 10.1016/S2352-3026(24)00247-3. [ DOI ] [ PubMed ] [ Google Scholar ] 54. Zhang S, Xiao X, Yi Y, Wang X, Zhu L, Shen Y, Lin D, Wu C. Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets. Signal Transduct Tar. 2024;9(1):149. doi: 10.1038/s41392-024-01848-7. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 55. Saini S, Gurung P. A comprehensive review of sensors of radiation-induced damage, radiation-induced proximal events, and cell death. Immunol Rev. 2025;329(1):e13409. doi: 10.1111/imr.13409. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 56. Guo J, Zhao Z, Shang ZF, Tang Z, Zhu H, Zhang K. Nanodrugs with intrinsic radioprotective exertion: turning the double-edged sword into a single-edged knife. Exploration (Beijing). 2023;3(2):20220119. doi: 10.1002/EXP.20220119. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 57. Goy E, Tomezak M, Facchin C, Martin N, Bouchaert E, Benoit J, de Schutter C, Nassour J, Saas L, Drullion C, et al. The out-of-field dose in radiation therapy induces delayed tumorigenesis by senescence evasion. Elife. 2022;11:11. doi: 10.7554/eLife.67190. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 58. Ding Y, Wang Y, Hu Q. Recent advances in overcoming barriers to cell-based delivery systems for cancer immunotherapy. Exploration. 2022;2(3):20210106. doi: 10.1002/EXP.20210106. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 59. Peng S, Lin A, Jiang A, Zhang C, Zhang J, Cheng Q, Luo P, Bai Y. CTLs heterogeneity and plasticity: implications for cancer immunotherapy. Mol Cancer. 2024;23(1):58. doi: 10.1186/s12943-024-01972-6. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 60. Li Y, Zhang C, Jiang A, Lin A, Liu Z, Cheng X, Wang W, Cheng Q, Zhang J, Wei T, et al. Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review. J Transl Med. 2024;22(1):293. doi: 10.1186/s12967-024-05104-y. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 61. Gao Z, Bai Y, Lin A, Jiang A, Zhou C, Cheng Q, Liu Z, Chen X, Zhang J, Luo P. Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment. Mol Cancer. 2023;22(1):31. doi: 10.1186/s12943-023-01722-0. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 62. Watkins T, Lim EL, Petkovic M, Elizalde S, Birkbak NJ, Wilson GA, Moore DA, Grönroos E, Rowan A, Dewhurst SM, et al. Pervasive chromosomal instability and karyotype order in tumour evolution. Nature. 2020;587(7832):126–132. doi: 10.1038/s41586-020-2698-6. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 63. Sanchez-Guixe M, Muinos F, Pinheiro-Santin M, González-Huici V, Rodriguez-Hernandez CJ, Avgustinova A, Lavarino C, González-Pérez A, Mora J, López-Bigas N. Origins of second malignancies in children and mutational footprint of chemotherapy in normal tissues. Cancer Discov. 2024;14(6):953–964. doi: 10.1158/2159-8290.CD-23-1186. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 64. Kutyna MM, Kok CH, Lim Y, Tran ENH, Campbell D, Paton S, Thompson-Peach C, Lim K, Cakouros D, Arthur A, et al. A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure. Leukemia. 2022;36(11):2678–2689. doi: 10.1038/s41375-022-01686-y. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 65. Martinez-Outschoorn U, Sotgia F, Lisanti MP. Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. Semin Oncol. 2014;41(2):195–216. doi: 10.1053/j.seminoncol.2014.03.002. [ DOI ] [ PubMed ] [ Google Scholar ] 66. Liu Y, Zhang X, Gu W, Su H, Wang X, Wang X, Zhang J, Xu M, Sheng W. Unlocking the crucial role of cancer-associated fibroblasts in tumor metastasis: mechanisms and therapeutic prospects. J Adv Res. 2025;71:399–413. doi: 10.1016/j.jare.2024.05.031. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 67. Raaijmakers K, Adema GJ, Bussink J, Ansems M. Cancer-associated fibroblasts, tumor and radiotherapy: interactions in the tumor micro-environment. J Exp Clin Canc Res. 2024;43(1):323. doi: 10.1186/s13046-024-03251-0. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 68. Zhang H, Yue X, Chen Z, Liu C, Wu W, Zhang N, Liu Z, Yang L, Jiang Q, Cheng Q, et al. Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials. Mol Cancer. 2023;22(1):159. doi: 10.1186/s12943-023-01860-5. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 69. Verginadis II, Avgousti H, Monslow J, Skoufos G, Chinga F, Kim K, Leli NM, Karagounis IV, Bell BI, Velalopoulou A, et al. A stromal integrated stress response activates perivascular cancer-associated fibroblasts to drive angiogenesis and tumour progression. Nat Cell Biol. 2022;24(6):940–953. doi: 10.1038/s41556-022-00918-8. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 70. Yu W, Biyik-Sit R, Uzun Y, Chen C-H, Thadi A, Sussman JH, Pang M, Wu C-Y, Grossmann LD, Gao P, et al. Longitudinal single-cell multiomic atlas of high-risk neuroblastoma reveals chemotherapy-induced tumor microenvironment rewiring. Nat Genet. 2025;57(5):1142–1154. doi: 10.1038/s41588-025-02158-6. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 71. Pich O, Cortes-Bullich A, Muinos F, Pratcorona M, Gonzalez-Perez A, Lopez-Bigas N. The evolution of hematopoietic cells under cancer therapy. Nat Commun. 2021;12(1):4803. doi: 10.1038/s41467-021-24858-3. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 72. Xiao Q, Liu Y, Shu X, Li Y, Zhang X, Wang C, He S, Li J, Li T, Liu T, et al. Molecular mechanisms of viral oncogenesis in haematological malignancies: perspectives from metabolic reprogramming, epigenetic regulation and immune microenvironment remodeling. Exp Hematol Oncol. 2025;14(1):69. doi: 10.1186/s40164-025-00655-2. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 73. Patel KK, Tariveranmoshabad M, Kadu S, Shobaki N, June C. From concept to cure: the evolution of CAR-T cell therapy. Mol Ther. 2025;33(5):2123–2140. doi: 10.1016/j.ymthe.2025.03.005. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 74. Lai M, Shao W, Mao J, Ye Q. Revolution in cell therapy: in vivo chimeric-antigen-receptor-T-cell therapy breakthroughs and promises for the future. Research-China. 2025;8:0917. doi: 10.34133/research.0917. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 75. Brudno JN, Maus MV, Hinrichs CS. Car T cells and T-cell therapies for cancer. JAMA. 2024;332(22):1924. doi: 10.1001/jama.2024.19462. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 76. Shen J, Hu R, Lin A, Jiang A, Tang B, Liu Z, Cheng Q, Miao K, Zhang J, Luo P. Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase. Eclinicalmedicine. 2024;73:102684. doi: 10.1016/j.eclinm.2024.102684. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 77. Braun T, Kuschel F, Reiche K, Merz M, Herling M. Emerging T-cell lymphomas after CAR T-cell therapy. Leukemia. 2025;39(6):1337–1341. doi: 10.1038/s41375-025-02574-x. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 78. Patel SA, Spiegel JY, Dahiya S. Second primary cancer after chimeric antigen receptor-T-cell therapy: a review. JAMA Oncol. 2025;11(2):174–181. doi: 10.1001/jamaoncol.2024.5412. [ DOI ] [ PubMed ] [ Google Scholar ] 79. Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, Morrissette JJD, Caponetti GC, Paruzzo L, Harris JC, Chong EA, Susanibar Adaniya SP, et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med. 2024;30(4):984–989. doi: 10.1038/s41591-024-02826-w. [ DOI ] [ PubMed ] [ Google Scholar ] 80. Chiesa R, Georgiadis C, Syed F, Zhan H, Etuk A, Gkazi SA, Preece R, Ottaviano G, Braybrook T, Chu J, et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N Engl J Med. 2023;389(10):899–910. doi: 10.1056/NEJMoa2300709. [ DOI ] [ PubMed ] [ Google Scholar ] 81. Chong EA, Alanio C, Svoboda J, Nasta SD, Landsburg DJ, Lacey SF, Ruella M, Bhattacharyya S, Wherry EJ, Schuster SJ. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood. 2022;139(7):1026–1038. doi: 10.1182/blood.2021012634. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 82. Elsallab M, Ellithi M, Lunning MA, D’Angelo C, Ma J, Perales M-A, Frigault M, Maus MV. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA adverse events reporting system. Blood. 2024;143(20):2099–2105. doi: 10.1182/blood.2024024166. [ DOI ] [ PubMed ] [ Google Scholar ] 83. Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, Patel M, Berthon A, Syed A, Yabe M, et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020;52(11):1219–1226. doi: 10.1038/s41588-020-00710-0. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 84. Reed SC, Croessmann S, Park BH. Chip happens: clonal hematopoiesis of indeterminate potential and its relationship to solid tumors. Clin Cancer Res. 2023;29(8):1403–1411. doi: 10.1158/1078-0432.CCR-22-2598. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 85. Cooperrider JH, Karaoglu DA, Kubicki T, Jiang CR, Postich E, Shimamoto K, Arnold O, Macaraeg J, Ramsland A, Pula A, et al. Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma. Leukemia. 2025;39(9):2285–2288. doi: 10.1038/s41375-025-02707-2. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 86. Schleicher WE, Hoag B, De Dominici M, Degregori J, Pietras EM. Chip: a clonal odyssey of the bone marrow niche. J Clin Invest. 2024;134(15):e180068. doi: 10.1172/JCI180068. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 87. Franco S, Godley LA. Genetic and environmental risks for clonal hematopoiesis and cancer. J Exp Med. 2025;222(1):e20230931. doi: 10.1084/jem.20230931. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 88. Hsu JI, Dayaram T, Tovy A, De Braekeleer E, Jeong M, Wang F, Zhang J, Heffernan TP, Gera S, Kovacs JJ, et al. PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy. Cell STEM Cell. 2018;23(5):700–713.e6. doi: 10.1016/j.stem.2018.10.004. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 89. Kahn JD, Miller PG, Silver AJ, Sellar RS, Bhatt S, Gibson C, McConkey M, Adams D, Mar B, Mertins P, et al. PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. Blood. 2018;132(11):1095–1105. doi: 10.1182/blood-2018-05-850339. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 90. Caiado F, Kovtonyuk LV, Gonullu NG, Fullin J, Boettcher S, Manz MG. Aging drives Tet2+/minus clonal hematopoiesis via IL-1 signaling. Blood. 2023;141(8):886–903. doi: 10.1182/blood.2022016835. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 91. Mcclatchy J, Strogantsev R, Wolfe E, Lin HY, Mohammadhosseini M, Davis BA, Eden C, Goldman D, Fleming WH, Conley P, et al. Clonal hematopoiesis related TET2 loss-of-function impedes IL1β-mediated epigenetic reprogramming in hematopoietic stem and progenitor cells. Nat Commun. 2023;14(1):8102. doi: 10.1038/s41467-023-43697-y. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 92. Sano S, Oshima K, Wang Y, MacLauchlan S, Katanasaka Y, Sano M, Zuriaga MA, Yoshiyama M, Goukassian D, Cooper MA, et al. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 inflammasome. J Am Coll Cardiol. 2018;71(8):875–886. doi: 10.1016/j.jacc.2017.12.037. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 93. Fujino T, Goyama S, Sugiura Y, Inoue D, Asada S, Yamasaki S, Matsumoto A, Yamaguchi K, Isobe Y, Tsuchiya A, et al. Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway. Nat Commun. 2021;12(1):1826. doi: 10.1038/s41467-021-22053-y. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 94. Zhong C, Wang L, Liu Y, Wang X, Xia Z, Li Y, Zhang Y, Liao J, Wang X, Liao C, et al. PSGL-1 is a phagocytosis checkpoint that enables tumor escape from macrophage clearance. Sci Immunol. 2025;10(108):eadn4302. doi: 10.1126/sciimmunol.adn4302. [ DOI ] [ PubMed ] [ Google Scholar ] 95. Bell HN, Zou W. Beyond the barrier: unraveling the mechanisms of immunotherapy resistance. Annu Rev Immunol. 2024;42(1):521–550. doi: 10.1146/annurev-immunol-101819-024752. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 96. Cords L, Engler S, Haberecker M, Rüschoff JH, Moch H, de Souza N, Bodenmiller B. Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer. Cancer Cell. 2024;42(3):396–412.e5. doi: 10.1016/j.ccell.2023.12.021. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 97. Locke FL, Filosto S, Chou J, Vardhanabhuti S, Perbost R, Dreger P, Hill BT, Lee C, Zinzani PL, Kröger N, et al. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma. Nat Med. 2024;30(2):507–518. doi: 10.1038/s41591-023-02754-1. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 98. Wang H, Wang X, Zhang X, Xu W. The promising role of tumor-associated macrophages in the treatment of cancer. Drug Resist Update. 2024;73:101041. doi: 10.1016/j.drup.2023.101041. [ DOI ] [ PubMed ] [ Google Scholar ] 99. Yang J, Xu J, Wang W, Zhang B, Yu X, Shi S. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets. Signal Transduct Tar. 2023;8(1):210. doi: 10.1038/s41392-023-01480-x. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 100. Bartolomucci A, Nobrega M, Ferrier T, Dickinson K, Kaorey N, Nadeau A, Castillo A, Burnier JV. Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. npj Precis Oncol. 2025;9(1):84. doi: 10.1038/s41698-025-00876-y. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 101. Li JY, Zuo LP, Xu J, Sun CY. Clinical applications of circulating tumor DNA in hematological malignancies: from past to the future. Blood Rev. 2024;68:101237. doi: 10.1016/j.blre.2024.101237. [ DOI ] [ PubMed ] [ Google Scholar ] 102. Dang DK, Park BH. Circulating tumor DNA: current challenges for clinical utility. J Clin Invest. 2022;132(12). doi: 10.1172/JCI154941. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 103. Lo Y, Han D, Jiang P, Chiu R. Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies. Science. 2021;372(6538). doi: 10.1126/science.aaw3616. [ DOI ] [ PubMed ] [ Google Scholar ] 104. Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, Diaz-Beya M, Juan M, Urbano-Ispizua Á, Esteve J, Velasco-Hernandez T, Menéndez P. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Tar. 2025;10(1):210. doi: 10.1038/s41392-025-02269-w. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 105. Rejeski K, Hill JA, Dahiya S, Jain MD. Noncanonical and mortality-defining toxicities of CAR T cell therapy. Nat Med. 2025;31(7):2132–2146. doi: 10.1038/s41591-025-03813-5. [ DOI ] [ PubMed ] [ Google Scholar ] 106. Dimitri A, Herbst F, Fraietta JA. Engineering the next-generation of car T-cells with CRISPR-Cas9 gene editing. Mol Cancer. 2022;21(1):78. doi: 10.1186/s12943-022-01559-z. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 107. Gu X, Wei S, Lv X. Circulating tumor cells: from new biological insights to clinical practice. Signal Transduct Tar. 2024;9(1):226. doi: 10.1038/s41392-024-01938-6. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 108. Gibson TM, Karyadi DM, Hartley SW, Arnold MA, Berrington de Gonzalez A, Conces MR, Howell RM, Kapoor V, Leisenring WM, Neglia JP, et al. Polygenic risk scores, radiation treatment exposures and subsequent cancer risk in childhood cancer survivors. Nat Med. 2024;30(3):690–698. doi: 10.1038/s41591-024-02837-7. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 109. Wong FL, Lee JM, Leisenring WM, Neglia JP, Howell RM, Smith SA, Oeffinger KC, Moskowitz CS, Henderson TO, Mertens A, et al. Health benefits and cost-effectiveness of Children’s Oncology Group breast cancer screening guidelines for chest-irradiated Hodgkin lymphoma survivors. J Clin Oncol. 2023;41(5):1046–1058. doi: 10.1200/JCO.22.00574. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 110. Winters DA, Soukup T, Sevdalis N, Green J, Lamb BW. The cancer multidisciplinary team meeting: in need of change? History, challenges and future perspectives. BJU Int. 2021;128(3):271–279. doi: 10.1111/bju.15495. [ DOI ] [ PubMed ] [ Google Scholar ] 111. Stirling RG, Harrison A, Huang J, Lee V, Taverner J, Barnes H. Multidisciplinary meeting review in nonsmall cell lung cancer: a systematic review and meta-analysis. Eur Respir Rev. 2024;33(172):230157. doi: 10.1183/16000617.0157-2023. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 112. Naughton C, Galvin R, Mccullagh R, Horgan F. Comprehensive geriatric assessment-where are we now, where do we need to be in the context of global ageing? Age Ageing. 2023;52(11). doi: 10.1093/ageing/afad210. [ DOI ] [ PubMed ] [ Google Scholar ] 113. Merli F, Luminari S, Tucci A, Arcari A, Rigacci L, Hawkes E, Chiattone CS, Cavallo F, Cabras G, Alvarez I, et al. Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the Fondazione Italiana Linfomi. J Clin Oncol. 2021;39(11):1214–1222. doi: 10.1200/JCO.20.02465. [ DOI ] [ PubMed ] [ Google Scholar ] 114. Lei P, Li W, Luo J, Xu N, Wang Y, Xie D, Guan H, Huang B, Huang X, Zhou P. Parp (poly ADP-ribose polymerase) family in health and disease. MedComm. 2025;6(9):eK0314. doi: 10.1002/mco2.70314. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 115. Ji S, Xiong M, Chen H, Liu Y, Zhou L, Hong Y, Wang M, Wang C, Fu X, Sun X. Cellular rejuvenation: molecular mechanisms and potential therapeutic interventions for diseases. Signal Transduct Tar. 2023;8(1):116. doi: 10.1038/s41392-023-01343-5. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 116. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD(+) metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Bio. 2021;22(2):119–141. doi: 10.1038/s41580-020-00313-x. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 117. Zoico E, Nori N, Darra E, Tebon M, Rizzatti V, Policastro G, De Caro A, Rossi AP, Fantin F, Zamboni M. Senolytic effects of quercetin in an in vitro model of pre-adipocytes and adipocytes induced senescence. Sci Rep-UK. 2021;11(1):23237. doi: 10.1038/s41598-021-02544-0. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 118. Zhang W, Qu J, Liu GH, Belmonte J. The ageing epigenome and its rejuvenation. Nat Rev Mol Cell Bio. 2020;21(3):137–150. doi: 10.1038/s41580-019-0204-5. [ DOI ] [ PubMed ] [ Google Scholar ] 119. Duffy MJ, Crown J. Circulating tumor DNA as a biomarker for monitoring patients with solid cancers: comparison with standard protein biomarkers. Clin Chem. 2022;68(11):1381–1390. doi: 10.1093/clinchem/hvac121. [ DOI ] [ PubMed ] [ Google Scholar ] 120. Garcia-Pardo M, Makarem M, Li J, Kelly D, Leighl NB. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges. Brit J Cancer. 2022;127(4):592–602. doi: 10.1038/s41416-022-01776-9. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 121. Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Bando H, Shirasu H, Yamazaki K, Watanabe J, Kotaka M, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med. 2023;29(1):127–134. doi: 10.1038/s41591-022-02115-4. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 122. Tang X, Gao L, Jiang X, Hou Z, Wang Y, Hou S, Qu H. Single-cell profiling reveals altered immune landscape and impaired NK cell function in gastric cancer liver metastasis. Oncogene. 2024;43(35):2635–2646. doi: 10.1038/s41388-024-03114-0. [ DOI ] [ PubMed ] [ Google Scholar ] 123. Sarawad A, Hosagoudar S, Parvatikar P. Pan-genomics: insight into the functional genome, applications, advancements, and challenges. Curr Genomics. 2025;26(1):2–14. doi: 10.2174/0113892029311541240627111506. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 124. Lyu G, Li D. Znf165: a pan-cancer biomarker with prognostic and therapeutic potential. Protein Peptide Lett. 2025;32(3):206–223. doi: 10.2174/0109298665351592250106062250. [ DOI ] [ PubMed ] [ Google Scholar ] 125. Li Y, Chen R, Zhang L, Jiang Y, Ren S, Li S, Xu H, Tan Y, Chen S, Tan X, et al. Intra-tumor DKK1 and CALML5 heterogeneity as a novel biomarker for prognosis and immunotherapy response in head and neck squamous cell carcinoma. Curr Mol Pharmacol. 2025;18(1):6–21. doi: 10.1016/j.cmp.2025.06.002. [ DOI ] [ Google Scholar ] 126. Yun J, Lee DS, Lee S, Yun H. Multiple primary cancers with hematologic malignancies and germline predisposition: a case series. Ann Lab Med. 2024;44(5):446–449. doi: 10.3343/alm.2023.0444. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 127. Long R, Zuo H, Tang G, Zhang C, Yue X, Yang J, Luo X, Deng Y, Qiu J, Li J, et al. Antibody-drug conjugates in cancer therapy: applications and future advances. Front Immunol. 2025;16:1516419. doi: 10.3389/fimmu.2025.1516419. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 128. Tsuchikama K, Anami Y, Ha S, Yamazaki CM. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol. 2024;21(3):203–223. doi: 10.1038/s41571-023-00850-2. [ DOI ] [ PubMed ] [ Google Scholar ] 129. Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Tar. 2022;7(1):93. doi: 10.1038/s41392-022-00947-7. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 130. Golmohammadi M, Raza S, Albayyadhi M, Sholehrasa H, Khouri J, Williams L, Hansen DK, Moradi A, Xu X, Albliwi M, et al. Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma. Blood Cancer J. 2025;15(1):130. doi: 10.1038/s41408-025-01334-5. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 131. Douglass J, Hsiue EH, Mog BJ, Hwang MS, DiNapoli SR, Pearlman AH, Miller MS, Wright KM, Azurmendi PA, Wang Q, et al. Bispecific antibodies targeting mutant RAS neoantigens. Sci Immunol. 2021;6(57). doi: 10.1126/sciimmunol.abd5515. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 132. Hsiue EH, Wright KM, Douglass J, Hwang MS, Mog BJ, Pearlman AH, Paul S, DiNapoli SR, Konig MF, Wang Q, et al. Targeting a neoantigen derived from a common TP53 mutation. Science. 2021;371(6533). doi: 10.1126/science.abc8697. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 133. Wang M, Zhao Y, Xu K, Liu C, Zhong H, Wu Y, Zhang K, Wei S. Cancer-associated fibroblasts in clear cell renal cell carcinoma: functional heterogeneity, tumor microenvironment crosstalk, and therapeutic opportunities. Front Immunol. 2025;16:1617968. doi: 10.3389/fimmu.2025.1617968. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 134. Glabman RA, Choyke PL, Sato N. Cancer-associated fibroblasts: tumorigenicity and targeting for cancer therapy. Cancers. 2022;14(16):3906. doi: 10.3390/cancers14163906. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 135. Lin A, Xiong M, Jiang A, Huang L, Wong HZH, Feng S, Zhang C, Li Y, Chen L, Chi H, et al. The microbiome in cancer. Imeta. 2025;4(5):e70070. doi: 10.1002/imt2.70070. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 136. Chen L, Lin A, Tang B, Li K, Qian Y, Liu X, Zhang Y, Deng Y, Chen W, Zhao Q, et al. The future of cancer therapy: nanomaterials and tumor microenvironment. iMetaMed. 2025;1(1). doi: 10.1002/imm3.70007. [ DOI ] [ Google Scholar ] 137. Bao Z, Li B, Qin T, Xu Z, Qu S, Jia Y, Li C, Pan L, Gao Q, Jiao M, et al. Molecular characteristics and clinical implications of TP53 mutations in therapy-related myelodysplastic syndromes. Blood Cancer J. 2025;15(1):58. doi: 10.1038/s41408-025-01276-y. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 138. Fu L, Zhou X, Zhang X, Li X, Zhang F, Gu H, Wang X. Circulating tumor DNA in lymphoma: technologies and applications. J Hematol Oncol. 2025;18(1):29. doi: 10.1186/s13045-025-01673-7. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 139. Denyer T, Timmermans M. Crafting a blueprint for single-cell RNA sequencing. Trends Plant Sci. 2022;27(1):92–103. doi: 10.1016/j.tplants.2021.08.016. [ DOI ] [ PubMed ] [ Google Scholar ] 140. Gohil SH, Iorgulescu JB, Braun DA, Keskin DB, Livak KJ. Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy. Nat Rev Clin Oncol. 2021;18(4):244–256. doi: 10.1038/s41571-020-00449-x. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 141. Simoes C, Chillon MC, Martinez-Cuadron D, Calasanz M-J, Vridiales M-B, Vazquez I, Hernández-Ruano M, Ariceta B, Aguirre-Ruiz P, Burgos L, et al. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia. Blood Adv. 2023;7(1):167–173. doi: 10.1182/bloodadvances.2022008141. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 142. Gao R, Bai S, Henderson YC, Lin Y, Schalck A, Yan Y, Kumar T, Hu M, Sei E, Davis A, et al. Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes. Nat Biotechnol. 2021;39(5):599–608. doi: 10.1038/s41587-020-00795-2. [ DOI ] [ PMC free article ] [ PubMed ] [ Google Scholar ] 143. Zhang H, Zhang J. Comprehensive omics profiling in acute myeloid leukemia: from molecular landscape to clinical translation. Curr Proteomics. 2025;22(3):100028. doi: 10.1016/j.curpro.2025.100028. [ DOI ] [ Google Scholar ] Associated Data This section collects any data citations, data availability statements, or supplementary materials included in this article. Data Availability Statement Data sharing is not applicable to this article as no new data were created or analyzed in this study. Articles from Human Vaccines & Immunotherapeutics are provided here courtesy of Taylor & Francis ACTIONS View on publisher site PDF (4.0 MB) Cite Collections Permalink PERMALINK Copy RESOURCES Similar articles Cited by other articles Links to NCBI Databases Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM Add to Collections Create a new collection Add to an existing collection Name your collection * Choose a collection Unable to load your collection due to an error Please try again Add Cancel Follow NCBI NCBI on X (formerly known as Twitter) NCBI on Facebook NCBI on LinkedIn NCBI on GitHub NCBI RSS feed Connect with NLM NLM on X (formerly known as Twitter) NLM on Facebook NLM on YouTube National Library of Medicine 8600 Rockville Pike Bethesda, MD 20894 Web Policies FOIA HHS Vulnerability Disclosure Help Accessibility Careers NLM NIH HHS USA.gov Back to Top